生物标志物可区分治疗性疫苗治疗的慢性乙型肝炎患者血清

StephenW

Cytokine. 2017 Nov 17. pii: S1043-4666(17)30346-0. doi: 10.1016/j.cyto.2017.11.004. [Epub ahead of print]
Biomarkers distinguish HBeAg seroconverted from non-converted individuals in chronic hepatitis B patients treated with a therapeutic vaccine.Zhou X1, Geng S2, Zhang S2, Zhao W2, Zhao G2, Wen Y2, Wang X3, Wang B4.
Author information1Institutes of Biomedical Sciences, Fudan University, Shanghai, China; Key Laboratory of Medical Molecular Virology of the Ministry of Health and the Ministry of Education, Shanghai Medical College, Fudan University, Shanghai, China.2Key Laboratory of Medical Molecular Virology of the Ministry of Health and the Ministry of Education, Shanghai Medical College, Fudan University, Shanghai, China.3Institutes of Biomedical Sciences, Fudan University, Shanghai, China. Electronic address: [email protected].4Key Laboratory of Medical Molecular Virology of the Ministry of Health and the Ministry of Education, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: [email protected].

AbstractCytokine assays of host immune responses to vaccination can indicate vaccine efficacy. Here we tested the hypothesis that assays of the cytokine status of infected individuals prior to therapeutic vaccination might provide a guide to vaccine therapeutic efficacy. If so, cytokine analysis might be used to select appropriate patients for therapeutic vaccination. Data were obtained from a panel of 14 cytokine/chemokine assays that were done during a phase III clinical trial of HBsAg-HBIG therapeutic vaccine (YIC) treatment of chronic hepatitis B (CHB) patients. Summarized assay results were compared between patients who responded by HBeAg-seroconversion and non-responders. Though no single cytokine or chemokine showed clear correlation with responsiveness, by bio-mathematical analysis with Boolean modelling, the combined results revealed that plasma IL-10, IL-33 and MIP-1α together correlated best with responsiveness. However, the difference between HBeAg seroconverted and non-converted YIC-treated CHB patients was maximized when results of all 14 cytokine/chemokine assays were included and showed a sensitivity around 0.59, and a specificity of 0.8. It suggested that the combined analysis of these elements may be useful to screen appropriate CHB patients for therapeutic vaccination with YIC.

Copyright © 2017 Elsevier Ltd. All rights reserved.

KEYWORDS: Antigen-antibody complex therapeutic vaccine; Biomarker; Boolean analysis model; Hepatitis B virus

PMID:29158122DOI:10.1016/j.cyto.2017.11.004

StephenW

细胞因子。 2017年11月17日。pii：S1043-4666（17）30346-0。 doi：10.1016 / j.cyto.2017.11.004。 [电子版提前打印]
生物标志物可区分治疗性疫苗治疗的慢性乙型肝炎患者血清转化的HBeAg和未转化的个体。
周X1，耿S2，张S2，赵W2，赵G2，文Y2，王X3，王B4。
作者信息

1
    上海复旦大学生物医学研究所;复旦大学上海医学院卫生部教育部医学分子病毒学重点实验室，中国上海
2
    复旦大学上海医学院卫生部教育部医学分子病毒学重点实验室，中国上海
3
    上海复旦大学生物医学研究所。电子地址：[email protected]。
4
    复旦大学上海医学院卫生部教育部医学分子病毒学重点实验室，中国上海电子地址：[email protected]。

抽象

宿主对接种免疫反应的细胞因子测定可以指示疫苗效力。在这里，我们测试了这样的假设，即在治疗性疫苗接种之前，感染个体的细胞因子状态的测定可以提供疫苗治疗功效的指导。如果是这样的话，可以使用细胞因子分析来选择合适的患者进行治疗性疫苗接种。数据来自于在HBsAg-HBIG治疗性疫苗（YIC）治疗慢性乙型肝炎（CHB）患者的III期临床试验期间进行的14种细胞因子/趋化因子测定的组。总结化验结果比较了HBeAg血清学转换的患者和无应答者。尽管没有单一的细胞因子或趋化因子与反应性有明显的相关性，但通过布尔模型的生物数学分析，综合结果显示血浆IL-10，IL-33和MIP-1α与反应性最好地相关。然而，当包含全部14种细胞因子/趋化因子测定的结果时，HBeAg血清转化的和未转化的YIC处理的CHB患者之间的差异最大化，并且显示约0.59的灵敏度和0.8的特异性。这表明这些元素的综合分析可能有助于筛选合适的CHB患者用YIC进行治疗性疫苗接种。

版权所有©2017 Elsevier有限公司保留所有权利。
关键词：

抗原 - 抗体复合物治疗性疫苗;生物标志物;布尔分析模型;乙型肝炎病毒

结论：
    29158122
DOI：
    10.1016 / j.cyto.2017.11.004